MedCity News is a trusted source for healthcare innovation news and analysis for busy professionals and senior executives.  

As the healthcare industry undergoes an overall transformation with an intense focus on value-based care, MedCity News reports on how the healthcare ecosystem – payers, providers, healthtech startups, investors, medtech, diagnostics and biopharma companies — are striving toward that goal. We get beyond the press releases to tell you how health IT startups, artificial intelligence companies, life science companies and hospitals are reimagining care to improve outcomes and reduce costs in a variety of chronic diseases like heart failure and diabetes as well as in cancer. We explain the latest trends in remote patient monitoring and clinical workflows.

MedCity News produces events that bring together the healthcare ecosystem and important stakeholders to share insights on challenges and opportunities in the industry. Check out our upcoming events here: https://events.medcitynews.com/.

For healthcare startups, we have created the MedCitizens community. As a member, you will be featured on MedCityNews.com and be able to reach our newsletter audience with regular updates about your company.

For experienced industry professionals and senior executives eager to showcase their thought leadership or a strong opinion, we have created the MedCity Influencers program. This outside contributors’ program is published on MedCityNews.com and circulated through our daily newsletter.  

Our daily newsletter reaches a senior industry audience and captures the news highlights of the day. Our weekly biopharma newsletter, BioPulse, is a weekly wrap of the most notable news in the industry in the week. Our StartUPDATES newsletter is focused on sharing news and updates from our MedCitizens. Sign up for our newsletters here: https://medcitynews.com/subscribe/.

JumpStart

Hatch Partners, LLC

Civic Innovation Lab

MedCity News

Ionis Pharmaceuticals’ olezarsen has Phase 3 results showing the therapy handily beat a placebo at reducing fat levels in the blood due to a rare, inherited metabolic disorder with no FDA-approved drugs. Ionis plans early 2024 submissions for what could become the first medicine it commercializes without a partner. http://ow.ly/aIa5104VJtr

The average monthly plan premium for Medicare Advantage is expected to increase only slightly in 2024 from 2023, CMS said. About 73% of beneficiaries will see no increase at all. http://ow.ly/r5uS104VJeG

Costco is partnering with Sesame to offer Costco Members discounted pricing on virtual health services, including primary care and mental health. But the move is a little different from other retailers like CVS Health and Walgreens. http://ow.ly/1G8S104VICu

Intercept Pharmaceuticals’ acquisition by Alphasigma comes three months after the FDA again rejected the biotech’s drug as a treatment for the fatty liver disease NASH. But Intercept still has rare liver disease assets, and Italy-based Alphasigma says acquiring the company will help it expand in gastroenterology and hepatology. http://ow.ly/3Ix0104VH3W

The advancement of value-based care cannot and should not exist solely in a payvider model, Intermountain Health CEO Rob Allen argued in an interview last week. Having its own health plan made things “a little easier” when Intermountain began getting serious about at-risk contracts, but achieving success in value-based care “is more about your commitment to the approach” and forging strong relationships with payers of all types. http://ow.ly/Fjur104VGxT

Rich Horgan believes that there’s an alternative path to drug development that can lower costs and the time it takes to bring drugs to market. He is trying to apply it to the field of rare and ultra-rare diseases. http://ow.ly/CoTc104VFFI

Digital therapeutics will be one of the topics discussed at INVEST Digital Health scheduled for October 26 at Health Wildcatters headquarters in Pegasus Park in Dallas. Register today! http://ow.ly/5UV7104VEQR

A new study found that MA beneficiaries have more than 50% fewer inpatient stays and 22% fewer emergency department visits than traditional Medicare enrollees. http://ow.ly/QtCX104VBrW

Novo Nordisk is paying Valo Health $60 million up front to gain three preclinical cardiovascular disease programs. Milestone payments for those programs and others covered under the artificial intelligence drug discovery pact could reach up to $2.7 billion. http://ow.ly/IeKW104VBcO

The Supreme Court’s recent summer decision in Health and Hospital Corporation of Marion County, Indiana, et al. v. Talevski has raised the stakes for nursing homes by ruling that private litigants may bring civil claims against facilities to recover damages for violations of certain provisions of the Federal Nursing Home Reform Act (FNHRA). This decision provides powerful incentives for nursing homes and other facilities subject to the FNHRA to enhance their monitoring and compliance processes. http://ow.ly/ci98104VB7b

BioIQ is a diagnostics startup in the point-of-care and home health testing market. They offer at-home tests and point-of-care tests with quick results. They have facilitated over 1 million Covid-19 tests and have partnerships with specialized laboratories.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:MEDCITYNEWS

BioIQ